{"id":"jmkx001899","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the S1P1 receptor, JMKX001899 modulates sphingosine-1-phosphate signaling, which plays a crucial role in various cellular processes, including immune cell trafficking and lymphocyte egress from lymphoid organs.","oneSentence":"JMKX001899 is a small molecule that targets the S1P1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:36.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT07242274","phase":"PHASE3","title":"Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2025-12-31","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":472},{"nctId":"NCT06946927","phase":"PHASE1","title":"A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation","status":"RECRUITING","sponsor":"Jemincare","startDate":"2025-06-06","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":72},{"nctId":"NCT06473948","phase":"PHASE1","title":"To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2024-07-10","conditions":"Solid Tumor, Adult","enrollment":27},{"nctId":"NCT06348290","phase":"PHASE1","title":"Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2024-04-01","conditions":"Solid Tumor, Adult","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"JMKX001899","genericName":"JMKX001899","companyName":"Jemincare","companyId":"jemincare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JMKX001899 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}